Gentronix Expands Specialist Sales Team in US and Europe
News Feb 17, 2012
Gentronix has expanding its sales teams with the appointments of Dorothy Zelent as Director of North American Operations, and Simon Johns as European Sales Director.
Reporting to Commercial Director, Dr. Steve Beasley, the company’s latest appointments lead the commercialization efforts in their respective territories.
With an extensive background in molecular biotechnology, Dorothy Zelent has over 10 years’ experience in academic and pharmaceutical research.
A graduate of the University of Pennsylvania, she previously conducted research into diabetes drug discovery before joining GlaxoSmithKline as a senior scientist in cardiovascular drug discovery.
Dorothy also brings broad project management skills to the role from previous positions as Director of Business Development for a number of clinical research technology companies.
European Sales Director, Simon Johns, has an impressive technical background in microbiology and genetics, as well as 20+ years’ international commercial experience supporting clients in the pharmaceutical, biotechnology and chemical sectors.
With his early research activities including the development of genotoxicity imaging systems, Simon has since worked extensively within the pre-clinical toxicology sector for several major global CROs in both Europe and the US.
Dr. Steve Beasley, Commercial Director at Gentronix comments, “Both Dorothy and Simon are experienced commercial professionals with a wealth of life sciences expertise, and we welcome them to the Gentronix team. We’re sure they will both make a significant contribution to the company’s strategy of growing the business, not only through the commercialization of our proprietary technologies, but also by expanding our service provision and continuing to establish collaborations in existing and new sectors.”
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE